UNSPSC 51201571: Blinatumomab

A bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory Bcell precursor acute lymphoblastic leukemia.

UNSPSC 51201571 Blinatumomab is a Commodity code that nominally covers a specific oncology pharmaceutical product, but the recent state and local opportunities tagged under it reflect no actual procurement of that drug. Instead, the solicitations posted under this code address athletic training services, first-aid medical supplies, and pharmacy benefit program intelligence—none of which align with blinatumomab's scope as a B-cell acute lymphoblastic leukemia therapeutic. The code shows little relevant recent activity; the mismatch between the code's nominal pharmaceutical product and the actual work being solicited suggests either erroneous tagging by the issuing bodies or a fundamental misalignment between the UNSPSC taxonomy and the buyers' internal classification practices.

The three recent opportunities span disparate issuing bodies and geographies with no coherent purchasing pattern under this code. The City of Tucson posted an RFP (due June 9, 2026) for comprehensive athletic training services for fire and police departments, the City of Tampa issued an ITB (posted April 24, 2026) for medical aid supplies including bandages, antiseptic, and first-aid kits with a total budget of $100,000 and set-asides for small local and minority-owned businesses, and the Texas Health and Human Services Commission posted a Request for Information (due April 3, 2026) to explore direct-to-manufacturer pharmacy programs. No pattern of state or local government demand for blinatumomab itself emerges from the record. Business development professionals should verify the correct UNSPSC code assignment before pursuing opportunities nominally listed under this commodity or consider whether the code is active in their target jurisdictions at all.